Nrx Pharmaceuticals Inc Stock Price, News & Analysis

NRx Pharmaceuticals (NASDAQ:NRXP) and its subsidiary HOPE Therapeutics conducted an investor workshop at Mar-A-Lago Club focused on HOPE's expansion plans for interventional psychiatry practices. The event, attended by Qualified Institutional Buyers, highlighted several key initiatives:

The company secured a $25 million financing commitment from Smith and Sauer, which is expected to leverage bank financing to secure $100 million in HOPE clinic revenue. The expansion strategy includes plans to add 50 clinics in 2026 and 100 clinics in 2027.

The discussion covered HOPE's mission to build an international network of EBITDA-positive interventional psychiatry clinics, recent clinic acquisitions, and plans for implementing CRM-based technology and telepsychiatry systems. A follow-up meeting is scheduled for late January 2025, expanding to include Accredited Investors.

NRx Pharmaceuticals (NASDAQ:NRXP) and its subsidiary HOPE Therapeutics have announced that Dr. Jonathan Javitt and Dr. David Feifel will deliver a keynote address at the 8th Annual Neuroscience Innovation Forum in San Francisco on January 12th, 2025. The presentation, titled 'Beyond Ketamine: Combined Interventional Treatment of Suicidal Depression and PTSD,' will focus on integrating NMDA-targeted drug therapy with emerging treatments like Transcranial Magnetic Stimulation and Digital Therapeutics.

Key developments include:

• A binding term sheet for $27 Million in anticipated funding for HOPE clinic acquisitions and pharmaceutical operations
• Planned acquisitions of Kadima Neuropsychiatry Institute and Dura Medical
• Initiation of NDA filing for NRX-100 (IV ketamine) for suicidal depression treatment

Upcoming milestones for Q1 2025 include the completion of NRX-100 filing, targeted NDA filing for NRX-101, and further HOPE clinic acquisitions.

HOPE Therapeutics and NRx Pharmaceuticals (NASDAQ:NRXP) have announced a binding term sheet with Smith & Sauer for $27 million in funding. The deal includes a $25 million Series A Preferred Stock purchase in HOPE Therapeutics, convertible into 1/3 of fully diluted equity, with a 15% preferred dividend for planned clinic acquisitions. Additionally, there's a $2 million investment in NRx equity at $2.75 per share.

The agreement includes warrants for 3 million unregistered NRx common stock shares at $3.00 per share with a 24-month term. Smith & Sauer will receive royalties on NRx product sales and will join both companies' Boards of Directors. The capital is expected to support HOPE clinic acquisitions and NRx Pharmaceutical operations, with management anticipating substantial revenue from clinic acquisitions in 2025.

HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals (NASDAQ: NRXP), announced plans to acquire Dura Medical as its first Florida acquisition. Dura Medical, founded in 2018 with clinics in Naples and Fort Myers, provides interventional psychiatry services including Ketamine Infusion Therapy, Transcranial Magnetic Stimulation, and Spravato®.

The acquisition is expected to be immediately accretive to revenue and EBITDA for NRx. Dura's founder, Stephen Durand, will serve as HOPE's Director of Clinical Growth for Florida. The company partners with the Veterans Affairs Community Cares Network, ensuring veterans have access to treatment for mental health conditions.

Dura Medical aims to treat more than 10,000 people by 2026. The acquisition is subject to financing, financial audits, definitive agreements, and standard closing conditions.

HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals (NASDAQ:NRXP), announces an upcoming investor workshop for Qualified Institutional Investors at Mar-A-Lago Club during the week of January 6, 2025. The event aims to support planned acquisitions for a national network of interventional psychiatry practices focused on treating suicidal depression and PTSD.

The company has secured non-binding Letters of Intent and banking intent for initial clinic acquisitions, targeting facilities that generate over $100 million revenue run-rate in 2025. Future acquisitions will focus on clinics with established patient populations offering multimodal care, including ketamine treatment and Transcranial Magnetic Stimulation (TMS).

The workshop requires a minimum commitment of $5 million in secured acquisition funding from qualified investors. The presentation will comply with JOBS act 'testing the waters' provisions, and federal security clearance will be required for attendance.

NRx Pharmaceuticals (NASDAQ:NRXP) announced its subsidiary HOPE Therapeutics plans to acquire Kadima Neuropsychiatry Institute in La Jolla, CA. The institute will serve as the flagship clinic for HOPE's planned international network of interventional psychiatry clinics treating depression, anxiety, and PTSD.

Kadima is a premier interventional psychiatry clinic offering treatments including Ketamine Therapy, Spravato®, and Transcranial Magnetic Stimulation. The institute has contracts with the US Department of Veterans Affairs and treats active-duty military personnel. The acquisition is expected to be immediately accretive to NRXP's revenue and EBITDA.

Dr. David Feifel, Kadima's founder and CEO, will join HOPE as Chief Medical Innovation Officer. Dr. Feifel, a Professor Emeritus of Psychiatry at UC San Diego with 150 peer-reviewed publications, will focus on evaluating new CNS disorder treatments and leading global clinical trials.

NRx Pharmaceuticals (NASDAQ:NRXP) has submitted the first section of its New Drug Application (NDA) for NRX-100 (ketamine) to the FDA for treating suicidal depression. The company aims to be the first to receive FDA approval for this indication, addressing a market of over 13 million Americans who consider suicide annually.

The initial submission includes an 1800-page manufacturing section (Module 3), with final efficacy data and remaining sections expected in Q1 2025. NRX-100's formulation differs from anesthetic ketamine by excluding toxic preservatives and featuring diversion-resistant packaging. The drug, which received Fast Track Designation in 2017, represents a potential $3-5 billion market based on CDC data indicating 3.8 million Americans plan suicide annually.

NRx Pharmaceuticals (NRXP) announced its participation in the NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference. Dr. Jonathan Javitt, Chairman, CEO and Chief Scientist, will present on December 3, 2024, at 1:00 PM EST at Florida Atlantic University. A high-definition video webcast will be available the following day on the company's website, Noble Capital Markets' Conference website, and Channelchek platform, where it will remain archived for 90 days.

NRx Pharmaceuticals announced the publication of a paper in the American Journal of Clinical Psychopharmacology highlighting their improved methodology for depression rating quality assurance in clinical trials. The company developed an enhanced training and monitoring program for study site raters that achieved 94.5% concordance with central raters, allowing for a maximum variance of 3 points on a 60-point scale. This improved accuracy enabled their phase 2b/3 clinical trial of NRX-101 to achieve statistical significance with fewer than 100 participants, compared to the several hundred typically required. The methodology demonstrated significant improvements in measuring recovery from suicidality and reduction in akathisia.